Sells it“Linzess (linaclotide) is a once-daily guanylate cyclase-C agonist used in adults to treat irritable bowel syndrome with constipation (IBS‑C) and chronic idiopathic constipation.”
Latest 10-KFY2025PositiveImpairment / charge ·
Skyrizi and Rinvoq more than offset Humira’s biosimilar losses; acquisition-related charges and a tax-rate reversal kept net earnings flat.
Revenue$61.2BYoY +8.6%
Net income$4.2BYoY −1.2%
Latest 10-QQ3 FY2026Positive ·
Skyrizi and Rinvoq more than offset Humira erosion; lower acquired R&D and impairment charges amplify the earnings rebound.
Revenue$17.4BYoY +10.3%
Net income$4.2Bvs $186.0M year ago
Latest 8-KLeadership change ·
Jennifer L. Davis resigned from AbbVie’s board following her appointment as Align Technology CEO.
Supplies it“Our relationships with leading partners like AbbVie, Takeda, Lundbeck, NVIDIA, Lambda, Revolution Medicines, Jazz Pharmaceuticals, and Bayer demonstrate meaningful external interest in our platform, and are expanding the impact of our platform to additional target classes (for example, G protein-coupled receptors), additional therapeutic indications (for example, neurology, gastrointestinal, inflammation and immunology), and additional small-molecule mechanisms of action (for example, molecular glues, and glue degraders).”